.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Advances in RAS Inhibition in Pancreatic Ductal Adenocarcinoma

Mike J. Pishvaian, MD, PhD, and Martin Dietrich, MD, PhD, explore emerging approaches to RAS inhibition in pancreatic ductal adenocarcinoma.

EP. 1: Explaining the Continued Interest in RAS Inhibition for PDAC

June 26th 2025

Mike J. Pishvaian, MD, PhD, and Martin Dietrich, MD, PhD, detail the continued interest in RAS inhibition for pancreatic ductal adenocarcinoma.

EP. 2: The Prevalence of RAS Mutations in Metastatic PDAC

July 10th 2025

Mike J. Pishvaian, MD, PhD, and Martin Dietrich, MD, PhD, discuss the prevalence of RAS mutations in pancreatic ductal adenocarcinoma.

EP. 3: The Current and Evolving Role of KRAS G12C and Pan-KRAS Inhibitors in Metastatic PDAC

July 24th 2025

Mike J. Pishvaian, MD, PhD, and Martin Dietrich, MD, PhD, discuss the evolving role of KRAS G12C and pan-KRAS inhibitors in pancreatic cancer.

EP. 4: How the Mechanisms of KRAS(ON) Inhibitors Differ From KRAS(OFF) Inhibitors

July 25th 2025

Mike J. Pishvaian, MD, PhD, and Martin Dietrich, MD, PhD, discuss how KRAS(ON) inhibitors differ in mechanism from KRAS(OFF) inhibitors.